New drug 9MW1911 tested for safety in first human trial

NCT ID NCT05803902

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 1 trial tested the safety and tolerability of a new drug called 9MW1911 in 48 healthy adults. The drug is being developed for asthma, COPD, and atopic dermatitis. Participants received either the drug or a placebo by IV infusion, and researchers monitored side effects and how the drug moves through the body.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

9MW1911 injection

What this could lead to

If successful, this could lead to a new treatment option for asthma, COPD, or atopic dermatitis.

What could go wrong

This is a very early Phase 1 trial in healthy people, not patients. It only checks safety and dosing, not whether the drug works for the diseases. Many drugs fail in later stages.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

asthma atopic eczema chronic obstructive pulmonary disease COPD, severe early onset

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Peking Union Hospital

    Beijing, Beijing Municipality, 100000, China